Abstract
Aims/hypothesis
The loss of pericytes surrounding the retinal vasculature in early diabetic retinopathy underlies changes to the neurovascular unit that lead to more destructive forms of the disease. However, it is unclear which changes lead to loss of retinal pericytes. This study investigated the hypothesis that chronic increases in one or more inflammatory factors mitigate the signalling pathways needed for pericyte survival.
Methods
Loss of pericytes and levels of inflammatory markers at the mRNA and protein levels were investigated in two genetic models of diabetes, Ins2Akita/+ (a model of type 1 diabetes) and Leprdb/db (a model of type 2 diabetes), at early stages of diabetic retinopathy. In addition, changes that accompany gliosis and the retinal vasculature were determined. Finally, changes in retinal pericytes chronically incubated with vehicle or increasing amounts of IFNγ were investigated to determine the effects on pericyte survival. The numbers of pericytes, microglia, astrocytes and endothelial cells in retinal flatmounts were determined by immunofluorescence. Protein and mRNA levels of inflammatory factors were determined using multiplex ELISAs and quantitative reverse transcription PCR (qRT-PCR). The effects of IFNγ on the murine retinal pericyte survival-related platelet-derived growth factor receptor β (PDGFRβ) signalling pathway were investigated by western blot analysis. Finally, the levels of cell death-associated protein kinase C isoform delta (PKCδ) and cleaved caspase 3 (CC3) in pericytes were determined by western blot analysis and immunocytochemistry.
Results
The essential findings of this study were that both type 1 and 2 diabetes were accompanied by a similar progression of retinal pericyte loss, as well as gliosis. However, inflammatory factor expression was dissimilar in the two models of diabetes, with peak expression occurring at different ages for each model. Retinal vascular changes were more severe in the type 2 diabetes model. Chronic incubation of murine retinal pericytes with IFNγ decreased PDGFRβ signalling and increased the levels of active PKCδ and CC3.
Conclusions/interpretation
We conclude that retinal inflammation is involved in and sustains pericyte loss as diabetic retinopathy progresses. Moreover, IFNγ plays a critical role in reducing pericyte survival in the retina by reducing activation of the PDGFRβ signalling pathway and increasing PKCδ levels and pericyte apoptosis.
Graphical Abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Diabetic retinopathy is one of the most common complications associated with both type 1 and type 2 diabetes, and is a leading cause of blindness worldwide [1]. Diabetic retinopathy is characterised as a disease of the retinal microvasculature, but it is accompanied by inflammation, oxidative stress, neuronal loss and gliosis [2]. There are two general forms of diabetic retinopathy. In order of their destructive influence, they are: (1) non-proliferative diabetic retinopathy, which may be further subdivided into mild, moderate and severe; and (2) proliferative diabetic retinopathy [3].
Pericytes, the contractile cells that cover the microvasculature, which is lined by endothelial cells, are one of the first cell types to be adversely affected by diabetes. A change in pericyte number is thought to underlie a cascade of early retinal vascular changes that occur during diabetes, including microaneurysms, thickening of the basement membrane, and loss of integrity of the blood–retina barrier and retinal neurons [4]. As the disease progresses, haemorrhaging, severe macular oedema, formation of hard exudates and cotton wool spots, continued neuronal loss, macro- and microgliosis, and neovascularisation occur [5]. Despite many valuable studies having been performed to try to understand the process by which the retinal pericytes are lost, mechanistic insight is lacking [4]. Both type 1 and type 2 diabetes involve hyperglycaemia, which leads to oxidative stress and the glycation of proteins and lipids [6]. Included among the glycated proteins is platelet-derived growth factor B (PDGFB), which is necessary for pericyte recruitment and survival [7]. While advanced glycated end-products (AGEs) lose their normal activity, they gain the ability to bind to the receptor for AGE (RAGE) or Toll-like receptor (TLR) 2 and/or 4 [8]. The RAGE and TLR pathways lead to increased transcription of proinflammatory genes [9]. Hyperglycaemia also increases the level of protein kinase C isoform delta (PKCδ), a member of the PKC family of kinases, involved in activating apoptosis of perivascular supporting cells [10]. While various inflammatory factors have been studied for their effects on the retinal vasculature, most of these studies were focused on later, more severe, stages in models of type 1 and type 2 diabetes [11]. Any potential role that inflammation may play in the early stages of the disease, particularly in pericyte loss, has not been clearly established.
To address the hypothesis that inflammation increases pericyte loss, we compared pericyte death, expression of inflammatory factors and glial activation in two genetic models of diabetes: Ins2Akita/+ (a model of type 1 diabetes) and Leprdb/db (a model of type 2 diabetes). The role of acute and chronic IFNγ treatment in platelet-derived growth factor receptor β (PDGFRβ) signalling was subsequently tested in vitro using murine retinal pericytes.
Methods
Animals
All experiments described were performed in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision Research as well as guidelines issued by the institutions involved. Three lines of male mice were used for these studies: (1) the Ins2Akita/+ mouse, which carries a spontaneous mutation in the insulin 2 gene on a C57Bl/6J background (C57BL/6-Ins2Akita/J; The Jackson Laboratory, USA; www.jax.org/strain/003548); (2) the Leprdb/db mouse model of type 2 diabetes, which carries a mutation in the gene encoding the leptin receptor on a background of C57Bl/6J (B6.BKS(D)-Leprdb/J; The Jackson Laboratory; www.jax.org/strain/000697); and (3) the immortomouse line, which carries a temperature-sensitive simian virus 40 (SV40) large T antigen (CBA;B10-Tg(H2Kb-tsA58)6Kio/Crl; Charles River Laboratories, USA; www.criver.com/sites/default/files/resources/doc_a/rm_rm_d_immunodeficient_models.pdf). C57BL/6J mice (The Jackson Laboratory; www.jax.org/strain/000664) were used as wild-type (WT) mice. Only male mice were used for these studies due to limitations previously described in both Ins2Akita/+ and Leprdb/db female mice [12, 13]. Specifically, both the Ins2Akita/+ and Leprdb/db mouse lines have been shown to be sexually dimorphic; female Leprdb/db mice have a severely reduced incidence of diabetes (only 12% of female Leprdb/db mice are hyperglycaemic) [12] and Ins2Akita/+ male mice on multiple backgrounds have been shown to have ‘more robust’ hyperglycaemia in comparison with female mice [13]. Prior to being killed, weight and blood glucose readings were recorded for the animal models of diabetes. A non-fasting glucometer reading of 13.88 mmol/l was considered to indicate hyperglycaemia (Table 1); both Ins2Akita/+ and Leprdb/db models were hyperglycaemic by 6 weeks of age. The PCR primers (metabion, Munich, Germany) used to identify heterozygous Ins2Akita/+, homozygous Leprdb/db and heterozygous immortomouse lines are given in Table 2. Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility in cages with four companions, and were kept on a 12 h light/dark cycle at 22°C with unrestricted access to standard mouse chow (LabDiet, USA) and water. Welfare assessments were performed daily. Animals were killed using CO2 and cervical dislocation.
Immunofluorescence and quantitative reverse transcription PCR
Information concerning primary antibodies and concentrations used are provided in Table 3. All antibodies were used as per manufacturers’ instructions. Retinal flatmount immunohistochemistry and analysis were performed as previously described [14]. Briefly, enucleated eyes were washed with 1× PBS, fixed in 4% paraformaldehyde (wt/vol.) at 4°C, rinsed with PBS and then stored at −20°C in methanol until used. Digital images were captured for 3–5 regions at a distance of 1–1000 µm away from the optic disc and >1000 µm away from the optic disc, and images were analysed using Fiji (2016; https://fiji.sc/) or Angiotool software (2016; https://ccrod.cancer.gov/confluence/display/ROB2/Downloads) to determine cell numbers (see electronic supplementary material [ESM] Fig. 1) [15]. Immunocytochemistry was performed as previously described [16]. For immunocytochemistry, cells were visualised using a Nikon Eclipse TE2000-U inverted microscope (Nikon Corporation, Japan). Primary antibodies were diluted in 2% serum (vol./vol.) diluted in 1× PBS and secondary antibodies were diluted in 0.3% Triton X (vol./vol.) in 1× PBS (PBST). The number of labelled cells in 20 fields was manually counted and divided by the total number of cells labelled with Hoechst stain to obtain the percentage of labelled cells. Quantitative reverse transcription PCR (qRT-PCR) was performed as previously described [14, 16]. The geometric means of the crossing threshold (Ct) values of three housekeeping genes, B2m, Sdha and Srp14, were used as endogenous controls to normalise expression between samples. Primers used for PCR are listed in Table 2.
Retinal pericyte isolation and culture
Mycoplasma-free murine retinal pericytes were isolated from the immortomouse line and grown as described previously [17]. Cells were maintained at 33°C and passaged every 3 days using 0.25% trypsin-EDTA. For assays testing the effects of IFNγ, cells were grown at 37°C, which is non-permissive for the expression of the SV40 large T antigen. For some experiments, cells were incubated with 1µl of vehicle (4 mmol/l HCl), 1µl PBS, 1 ng, 25 ng, 50 ng or 100 ng mouse IFNγ, and/or 50 ng/ml of recombinant human platelet-derived growth factor B homodimer (PDGFBB) (R&D Systems, MN, USA). Cultures treated with high glucose and osmotic controls (5.7 mmol/l d-glucose + 35 mmol/l l-glucose) and/or IFNγ were grown for 5 days, as described previously [18].
Immunoblotting
Western blots were performed as previously described with minor modifications in the Revert Total Protein Stain and antigen pretreatment procedures [16]. All antibodies were used as per manufacturers’ instructions. Specifically, membranes were blocked with either 5% milk (wt/vol.) in TBS Tween 20 (TBST; 20 mmol/l Tris base pH 7.6, 137 mmol/l sodium chloride, 0.1% Tween 20 [vol./vol.]) or 10% BSA in TBST, for 1 h at room temperature. After blocking, membranes were incubated with primary antibody diluted in TBST overnight, at 4°C, on a shaker. Blots were then washed three times for 10 min and once for 5 min in TBST, incubated with SuperSignal West Femto or SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific, USA), and visualised on autoradiography film (Bio Dot Blue Lite, Dot Scientific, Burton, MI, USA). β-Tubulin was used as a loading control for the majority of blots, except for PKCδ immunoblots, whereby Revert Total Protein Stain (LI-COR, Lincoln, NE, USA) was used as a loading control, as per manufacturer’s instructions. Membranes probed for p-PDGFRβ were washed three times with ultrapure water and incubated with the antigen pretreatment solution in the SuperSignal Western Blot Enhancer kit (Thermo Fisher Scientific; catalogue no. 46641) for 10 min at room temperature, before washing five times with ultrapure water prior to the blocking step. In addition, membranes probed for p-PDGFRβ were incubated with the antigen pretreatment solution in a western blot enhancer signal kit (Thermo Fisher Scientific; catalogue no. 46641) for 10 min at room temperature prior to the blocking step.
Multiplex ELISA
Levels of cytokines were measured from retinal samples using V-PLEX Proinflammatory Panel 1 ELISA Meso Scale Discovery (MSD) electrochemiluminescence kits (Meso Scale Diagnostics, Rockville, MD, USA; catalogue no. K15048D-1). Retinal samples from 6- and 12-week-old WT), Ins2Akita/+ and Leprdb/db mice were dissected free of other tissues, flash-frozen in liquid nitrogen, and kept at −80°C prior to protein extraction and ELISA. Both retinas from the same mouse were pooled together to obtain enough protein to run the ELISA assays.
Study design and statistics
Samples used for quantification of retinal flatmounts, ELISAs and western blots were not randomised and the investigator was not blinded. In vitro samples were not randomised but the investigator was blind to the condition of the cells counted. Cell count data, qRT-PCR data and western blot densitometry data were analysed by one-way ANOVA [19] with Tukey’s test for post hoc analysis using Prism 9 (Prism 9.4.1; GraphPad Software, USA). Grubbs’ analysis was routinely run on all cell count, qPCR, western blot and ELISA data. Grubbs’ analysis identified an outlier in ELISA-derived data for proinflammatory proteins in whole retinal samples (Fig. 2) using GraphPad Prism. A p value ≤0.05 was considered statistically significant. Immunoassay data were fitted to an ANOVA model, with genotype, time (week) and their interaction as model terms. Comparisons were made between different genotypes at the same time points, or over time for the same genotype. The p values were not adjusted for multiple testing. Data are expressed as means with SEM, as indicated in the figure legends.
Results
Pericyte loss was evident at 3 weeks of age in retina of Ins2 Akita/+ and Lepr db/db models
Pericyte loss is an early marker of diabetic retinopathy in models of diabetes; however, a quantitative analysis of earlier timepoints in genetic models is lacking [20]. Early stages of the disease were designated as 12 and 18 weeks of age, and 24 weeks of age was designated as an intermediate stage, based on features such as pericyte loss, basement membrane thickening and changes to blood flow as described in other studies [21]. In this study, we refer to the age of the mice rather than the number of weeks the animals have had diabetes; however, Table 4 shows the conversion of age to number of weeks with diabetes for each genotype. Ins2Akita/+ mice become hyperglycaemic at 4 weeks of age. All of the Leprdb/db mice in our study were hyperglycaemic by 6 weeks of age, although The Jackson Laboratory indicates that the mice can become hyperglycaemic between 4 and 8 weeks of age. Pericyte loss in WT mice, and models of type 1 and type 2 diabetes was compared using the Ins2Akita/+ and Leprdb/db models. To quantify retinal pericytes in the early progression of the disease, retinas were obtained from Ins2Akita/+ and Leprdb/db mice at 3, 6, 12, 18 and 24 weeks, and retinal flatmounts were immunolabelled for neural-glial antigen 2 (NG2; Fig. 1a and ESM Fig. 2). Quantification of these samples indicated a loss of pericytes as early as 3 weeks of age and continuing up to 12 weeks (Fig. 1a). In non-diabetic retinas, the mean number of NG2+ cells per 520 μm2 was 85±4, whereas in diabetic retina from 3-week-old Ins2Akita/+ and Leprdb/db mice, the number of NG2+ cells was reduced to 71 (±4) and 63 (±2), respectively. At 6 weeks, the mean number of NG2+ cells increased in the WT to 94±3, but continued to decrease in the Ins2Akita/+ (61±3) and Leprdb/db (58±2) mice. The number of pericytes continued to decrease, with the lowest numbers being observed at 12 weeks of age in both the Ins2Akita/+ mice (59±4) and Leprdb/db (49±4) mice vs non-diabetic levels (92±4). At 18 and 24 weeks of age, levels of NG2+ cells in samples from Ins2Akita/+ (62±4.7 and 58±4, respectively) and Leprdb/db (54±3 and 59±4, respectively) mice were not statistically different from 12 week samples. When compared with changes in blood glucose levels (Table 1), the number of pericytes began to decrease prior to the mice becoming notably hyperglycaemic.
Proinflammatory markers increased in retinas of Ins2 Akita/+ and Lepr db/db mice at early stages of diabetes
To determine the time course of retinal inflammation in the various mouse lines, RNA was isolated from WT, Ins2Akita/+ and Leprdb/db retinas at 3, 6, 12, 18 and 24 weeks of age and the samples were subjected to qRT-PCR to analyse mRNA levels of secreted proinflammatory cytokines and chemokines that are known to change in those with diabetes, including colony-stimulating factor (encoded by Csf1 [also known as Csf]), granulocyte macrophage colony-stimulating factor (encoded by Csf2 [also known as Gm-csf]), IFNα (Ifna [Ifnα]), IFNγ (Ifng [Ifnγ]), IL-1β (Il1b [Il1β]), IL-6 (Il6), vascular endothelial growth factor (Vegfa [Vegf]), C–C motif chemokine ligand 5 (Ccl5) and thrombospondins 1 and 2 (Thbs1 and Thbs2) [11, 22]. In addition, the levels of two markers that respond to proinflammatory signalling, Irf8 and Aif1 (also known as Iba1), were also determined [23, 24]. In retinas of the Ins2Akita/+ mice, there were no statistically significant increases in inflammatory markers at 3 weeks of age relative to control littermates (Fig. 1b). In contrast, by 6 weeks of age, there were significant increases in the levels of Ifnγ and Ccl5 in comparison with WT littermates. The peak increase in mRNA levels occurred for many of the markers at 12 weeks of age, with increases in Csf, Gm-csf, Il6, Vegf and Irf8 relative to WT littermates. At 18 weeks of age, Ins2Akita/+ retinas continued to show elevated levels of Csf, Gm-csf, Il1β and Cd68. Samples from 24-week-old Ins2Akita/+ mice showed reductions in mRNA, with levels close to or below baseline levels.
In comparison with the retinas from Ins2Akita/+ mice, those from Leprdb/db mice showed marked differences in the mRNA levels of inflammatory markers (Fig. 1c). At both 3 and 24 weeks of age, many proinflammatory mRNAs appeared to be reduced relative to WT littermates. At 3 weeks of age, there were significantly decreased levels of Csf, Vegf, Ccl5, Thbs1, Thbs2 and Iba1. There were also reductions in Gm-csf, Ifnα, Ifnγ, Il1β, Il6, Cd68 and Irf8 relative to WT littermates, although these were not significant. Similar to samples from 3-week-old mice, at 24 weeks of age, there were significantly decreased levels of Csf, Gm-csf, Ifnα, Ifnγ, Vegf, Cd68, Thbs1, Irf8 and Iba1. At 6, 12 and 18 weeks of age, there were incremental increases in many of the mRNAs, with the peak appearing at around 18 weeks of age.
To examine potential changes in levels of proinflammatory factors at the protein level, multiplex ELISAs were analysed using whole retinal samples from 6- and 12-week-old diabetic Ins2Akita/+ and Leprdb/db mice and WT mice (Fig. 2). In retinas from 6-week-old Ins2Akita/+ mice, there were significant increases in the levels of IFNγ, IL-1β and keratinocyte chemoattractant/growth-regulated oncogene (KC-GRO) compared with WT samples. In comparison, there were significant decreases in IL-5, IL-6 and IL-12p70 in retinas from 6-week-old Leprdb/db mice compared with WT mice. Similar to mRNA levels, there was an overall decrease in the levels of proinflammatory factors found in the retinas of the Leprdb/db mice; however, most findings did not reach statistical significance. At 12 weeks of age, IFNγ was the only factor that was significantly increased in the Ins2Akita/+ mice vs control littermates (Fig. 2). IFNγ was also the only proinflammatory factor that increased in Leprdb/db mice in comparison with WT littermates, but the difference was not statistically significant.
Increases in proinflammatory chemokines and cytokines may be accompanied by changes to microglia numbers and/or infiltration of macrophages to the retina [23]. To determine whether there were changes to the number of cells of the myeloid lineage, retinal flatmounts from 3-, 6-, 12-, 18- and 24-week-old Ins2Akita/+ and Leprdb/db mice were immunolabelled with an antibody recognising ionised calcium binding adaptor molecule 1 (IBA1; ESM Fig. 3). Analysis of cell counts from WT vs Ins2Akita/+ samples indicated there were no significant differences in the number of IBA1+ cells at any of the stages examined (Fig. 3a). In contrast, a small decrease in the number of IBA1+ cells was observed in Leprdb/db mice at 3 weeks of age (41.6±1.2) vs WT mice (48.2±2.9) , while, at 12 weeks of age, there was a small increase in the mean number of IBA1+ cells in Leprdb/db mice (46.0±1.6) vs WT mice (40.2±1.0). All other time points showed no differences in the number of IBA1+ cells in WT and Leprdb/db mice.
Gliosis was apparent in Ins2 Akita/+ and Lepr db/db samples between 6 and 18 weeks of age
Proinflammatory states are frequently accompanied by an activated state of astrocytes, termed gliosis, in which the cells de-differentiate, increase expression of growth factors and pro- and anti-inflammatory factors, and, in some cases, proliferate [25]. To determine whether there were changes to the number of astrocytes, retinal flatmounts from 3-, 6-, 12-, 18- and 24-week-old Ins2Akita/+ and Leprdb/db mice were immunolabelled using antibodies specific for the transcription factor sex-determining region Y-box 2 (SOX2), a marker for astrocytes, cholinergic amacrine cells and progenitor cells [26]. In comparison with WT mice, retinas from Ins2Akita/+ and Leprdb/db mice showed no statistically significant changes in the number of SOX2+ cells (Fig. 3b and ESM Fig. 4).
To determine the presence of gliosis, qRT-PCR was used to analyse mRNA levels of markers that are known to change during gliosis; analyses were carried out in retinal samples obtained from 3-, 6-, 12-, 18- and 24-week-old Ins2Akita/+ and Leprdb/db mice [27, 28]. In 3-week-old Ins2Akita/+ mice, there was an increase in the level of Ptprz1 (encoding phosphocan; also known as Pcan) in comparison with WT mice. In addition, Gfap (encoding glial fibrillary acidic protein) was elevated in the retinas of 6-week-old Ins2Akita/+ mice, although this difference was not significant. Similar to the results for mRNA levels of inflammatory markers, the peak in levels of mRNA associated with gliosis in Ins2Akita/+ mice appeared at 12 weeks of age, with increases in Tlr4 (encoding TLR4), Pcan and Mmp14 (encoding matrix metalloproteinase 14). Although some mRNA levels were still increased in samples from 18- and/or 24-week-old mice vs WT, the observed increases were not as great when compared with samples from 12-week-old mice.
In retinal samples from Leprdb/db mice, there were some overall similarities between the data for mRNA levels of gliosis markers (Fig. 3d) vs inflammatory markers (Fig. 1), in that many of the mRNAs appeared to be unchanged or reduced in comparison with WT samples at 3 and 24 weeks of age, whereas multiple markers were increased in samples from 6-, 12- and 18-week-old Leprdb/db mice (Fig. 3d). Gliosis markers that were significantly decreased in Leprdb/db in comparison with samples from 24-week-old WT littermates included Gfap, Glul (encoding glutamine synthetase; also known as Gs), Vim (encoding vimentin), Egfr (encoding epidermal growth factor receptor), Ncan (encoding neurocan), Pcan, Timp2 (encoding tissue inhibitor of metalloproteinase 2) and Mmp14. At 6 weeks of age, the retinas of Leprdb/db mice had increased levels of Gfap, S100b (encoding S100 calcium-binding protein B), and Egfr, but these differences were not significant. At 12 weeks of age, there were increases in Gs and Egfr in Leprdb/db vs WT, while at 18 weeks of age there were small increases in Gfap, Egfr and Mmp14, and decreases in S100b, Vim, Ncan, Pcan and Timp2. As with the retinal samples from Ins2Akita/+ mice, the peak increases in gliosis markers in Leprdb/db mouse-derived retinas was observed at 12 weeks of age, specifically in Gs and Egfr, whereas levels for Gfap, Egfr and Mmp14 were slightly increased at 18 weeks of age in comparison with WT samples.
Retinal vasculature was altered at early timepoints in Ins2 Akita/+ and Lepr db/db models
Retinal microvascular abnormalities are commonly associated with diabetes, and include microaneurysms, haemorrhaging, intraretinal vascular abnormalities and neovascularisation in humans [29]. Retinas of Ins2Akita/+ and Leprdb/db mice were immunolabelled with isolectin B4 (IB4) and the flatmounts of samples obtained at 6, 12, 18 and 24 weeks of age were analysed for percentage of retinal area covered by IB4+ cells and branch numbers using Angiotool software [30]. Retinas from Ins2Akita/+ mice showed no change in the percentage of retinal area covered by superficial vascular plexus until 24 weeks, at which time the percentage of retinal area covered by vasculature in Leprdb/db samples was 25.80±1.0 in comparison with retinas of WT mice, in which 18.95±0.51 of retinal area was covered. In contrast, Leprdb/db samples showed an increase at 6 weeks in comparison with WT and Ins2Akita/+ samples (Fig. 4a and ESM Fig. 5). The percentage area covered by IB4+ cells appeared to normalise in samples from 12- and 18-week-old mice but increased again at 24 weeks of age in comparison with WT mice. In Leprdb/db samples, there was an increase in the percentage of area covered at 6 (27.16±2.27) and 24 weeks of age (23.68±1.02) in comparison with WT at the same ages, respectively (21.4±1.06 and 18.96±0.51). For branch number, the retinas of Ins2Akita/+ mice were similar to those of WT mice, with slight increases at 6 and 24 weeks of age (Fig. 4b). In contrast, the retinas of Leprdb/db mice consistently showed an increase in branch number in comparison with WT at 6, 12 and 18 weeks of age.
Treatment with IFNγ altered PDGFRβ signalling in pericytes
In the studies presented here, IFNγ levels were increased in both the Ins2Akita/+ and Leprdb/db models at early stages of diabetes. To test the role of acute treatment with increasing concentrations of IFNγ in PDGFRβ signalling, isolated murine retinal pericytes were cultured and incubated with IFNγ for 24 h, incubated with PDGFBB for 20 min, and assayed for activation of PDGFRβ and downstream signalling pathways including PKB/Akt and mitogen-activated protein kinase (MAPK)/ERK1/2. No differences in PDGFRβ signalling were found between vehicle- and IFNγ-treated cells following 24 h of treatment (ESM Fig. 6). To determine whether longer exposure to IFNγ that mimicked chronic exposure perturbed PDGFRβ signalling, cells were treated with 1 ng, 25 ng or 50 ng of IFNγ for 72 h, followed by treatment with PDGFBB for 20 min. Lysates were again probed for PDGFRβ (Fig. 5a), Akt and p-Akt (Fig. 5b), or ERK1/2 and pERK1/2 (Fig. 5c). Densitometry readings normalised to β-tubulin indicated no changes in total levels of PDGFRβ, Akt or ERK1/2. Vehicle-treated samples showed no detectable level of p-PDGFRβ, and samples incubated with IFNγ alone showed a low level of p-PDGFRβ. In contrast, the ratio of normalised p-PDGFRβ to normalised total PDGFRβ had decreased in all IFNγ and PDGFBB co-treated samples in comparison with control samples (Fig. 5a). In addition, the ratios of p-Akt to total Akt and of pERK1/2 to total ERK1/2 showed statistically significant decreases in the 50 ng IFNγ+PDGFBB co-treatment conditions (Fig. 5b,c).
Chronic IFNγ treatment induced PKCδ expression and reduced pericyte survival
An increase in the level of PKCδ has specifically been tied to pericyte loss in diabetic retinopathy [10]. To test the hypothesis that IFNγ may drive an increase in the levels of PKCδ, cultured pericytes were again incubated with 1 ng, 25 ng or 50 ng of IFNγ for 72 h in the presence of PDGFBB, and lysates were probed with an antibody that recognises the full-length and cleaved, activated forms of PKCδ (Fig. 5d). The mean densitometry levels of PKCδ were low in samples treated with vehicle or PDGFBB alone; however, relative levels increased significantly in samples treated with IFNγ alone and in the IFNγ+PDGFBB co-treated samples.
An increase in cleaved PKCδ suggests increased cell death associated with IFNγ treatment. To verify this, proliferation and cell death were directly assessed. Pericytes were grown in vehicle, 1 ng, 25 ng or 50 ng of IFNγ for 72 h in the presence of PDGFBB, and fixed cells were immunolabelled for cleaved caspase 3 (CC3) or proliferating cell nuclear antigen (PCNA). The number of positive cells for each marker was quantified as a percentage of the total number of cells (ESM Fig. 7). Vehicle-treated cells showed less than 1% of CC3+ cells (ESM Fig. 7a). In contrast, cells treated with IFNγ alone or with PDGFBB showed increasing numbers of CC3+ cells, concomitant with increasing concentrations of IFNγ (ESM Fig. 7a). No change in the percentage of PCNA+ cells was noted in IFNγ- and vehicle-treated pericytes (ESM Fig. 7b).
To investigate the role of IFNγ under hyperglycaemic conditions, pericytes were grown with vehicle or 1 ng, 25 ng or 50 ng of IFNγ in physiologically normal medium (5.7 mmol/l d-glucose), high-glucose medium (40.7 mmol/l d-glucose) or an osmotic control (35 mmol/l l-glucose with 5.7 mmol/l d-glucose), and the number of CC3+ pericytes was quantified as a percentage of total cells (Fig. 6). Under high-glucose conditions, vehicle-treated cells showed an increased percentage of CC3+ cells in comparison with vehicle-treated cells under normal glucose and osmolarity control conditions, while all cultures treated with 25 ng or 50 ng IFNγ showed an increase in percentage of CC3+ pericytes in comparison with those treated with vehicle or 1 ng IFNγ.
Discussion
Levels of IFNγ are increased in individuals with diabetes with diabetic retinopathy, but not in those with diabetes without diabetic retinopathy, and are increased in both type 1 and type 2 diabetes [31]. The mechanisms by which IFNγ supports the development of diabetic retinopathy have not been investigated. Previous work from the Sheibani laboratory demonstrated that inflammation was the primary initiating factor in pericyte death under high-glucose conditions, and that Bcl-2 interacting mediator of cell death (BIM) and PKCδ were critical to pericyte death [18]. The study presented here extends those findings, and indicates that IFNγ is critical to the loss of pericytes and that the mechanism underlying this loss may, in part, involve a loss of PDGFRβ signalling.
Type 1 diabetes is an autoimmune disease in which multiple immune cells contribute to the accumulation of inflammatory molecules and the eventual destruction of the pancreatic beta cells [32]. In contrast, visceral white adipose tissue is the major source of inflammation in type 2 diabetes, as the tissue is infiltrated by macrophages and T and B cells [32]. The involvement of different inflammatory agents and the timeline on which they accumulate may indicate which organs become involved and the time point at which they become involved. This may partially explain why there appears to be a reduced inflammatory response at 6 and 24 weeks of age in the Leprdb/db model. Evidence suggests that there are elevated levels of anti-inflammatory factors in various disease states, including type 2 diabetes, and that the levels of these factors fluctuate [33]. TNF-α and IL-1β have often been mentioned as playing a key role in both type 1 and type 2 diabetes, and IFNγ is another proinflammatory factor that is critical to the pathogenesis of both types of diabetes, but has not been extensively studied in diabetic retinopathy [34].
A comparative analysis between humans and rodents indicates that proinflammatory factors such as TNF-α, IL-1β and IL-6 are correlated with diabetic retinopathy. All three factors are very prominent in proliferative diabetic retinopathy in humans [35,36,37,38]. Vinores’ group investigated streptozotocin (STZ)-treated mice and Ins2Akita/+ mice with a TNF-α knockout, showing that there was a reduction in leucostasis by 1–2 weeks of diabetes, but TNF-α does not affect blood–retina barrier breakdown or CC3 levels until 3 months of development [39]. Regarding IL-6, 72 vitreal proteins were shown to be altered in mice treated with STZ as compared with controls; however, in 52 of the 72 proteins, these effects were mitigated in mice treated with an IL-6 inhibitor 10 weeks after STZ treatment, indicating the importance of IL-6 at the 10-week timepoint following diabetes induction [40]. In addition, several studies have quantified IL-1β levels in STZ-treated rats, showing that there was an increase in IL-1β at various times following STZ treatment [41, 42]. An in vitro investigation of IL-1β indicated that it may play a role in apoptosis of retinal endothelial cells [42].
Hyperglycaemia and chronic inflammation, arising in both type 1 and type 2 diabetes, are thought to initiate injury within the retinal neurovascular unit, including breakdown of the blood–retina barrier, vascular damage, increase in retinal inflammation, gliosis and neuronal loss. The byproducts of hyperglycaemia, AGEs, regulate inflammation by increasing NF-κB nuclear localisation and induction of IL-1β, TNF-α, macrophage inflammatory protein 2 (MIP2), IL-6 and IL-10 [43]. Increases in serum levels of TNF-α and IL-1β can induce adhesion of leucocytes to capillaries and lead to vascular leakiness, oedema and capillary non-perfusion [44]. IFNγ levels are increased in serum, tears, and the vitreous and aqueous humours of individuals with diabetes with retinopathy, but not in those with diabetes without retinopathy [31]. These findings have led to the proposal that IFNγ promotes and sustains chronic inflammation in diabetic retinopathy.
Evidence from our study indicates that IFNγ may also be important in mouse models of diabetic retinopathy. Specifically, we found that Ifnγ mRNA levels are increased in both the Ins2Akita/+ and Leprdb/db models and IFNγ protein levels are increased in the Ins2Akita/+ model. In addition, we found that IFNγ reduces PDGFRβ signalling, subsequently leading to a loss of pericytes. The fact that IFNγ levels are not increased until after a reduction in pericytes may reflect: (1) a change in the number of pericytes that have completed differentiation due to a loss of PDGFRβ signalling; (2) IFNγ-initiated pericyte loss prior to the increase in retinal inflammation; or (3) that other factors, alone or in conjunction with IFNγ, are important in the initiation of pericyte loss. Future experiments will be important in distinguishing between these possibilities.
Abbreviations
- AGE:
-
Advanced glycated end-product
- CC3:
-
Cleaved caspase 3
- IB4:
-
Isolectin B4
- IBA1:
-
Ionised calcium binding adaptor molecule 1
- NG2:
-
Neural-glial antigen 2
- PCNA:
-
Proliferating cell nuclear antigen
- PDGFB:
-
Platelet-derived growth factor B
- PDGFBB:
-
Platelet-derived growth factor B homodimer
- PDGFRβ:
-
Platelet-derived growth factor receptor β
- PKCδ:
-
Protein kinase C isoform delta
- qRT-PCR:
-
Quantitative reverse transcription PCR
- RAGE:
-
Receptor for advanced glycated end-products
- SOX2:
-
Sex-determining region Y-box 2
- STZ:
-
Streptozotocin
- SV40:
-
Simian virus 40
- TLR:
-
Toll-like receptor
- WT:
-
Wild-type
References
Cheloni R, Gandolfi SA, Signorelli C, Odone A (2019) Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. BMJ Open 9(3):e022188. https://doi.org/10.1136/bmjopen-2018-022188
Nian S, Lo ACY, Mi Y, Ren K, Yang D (2021) Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets. Eye Vis 8(1):15. https://doi.org/10.1186/s40662-021-00239-1
Sabanayagam C, Banu R, Chee ML et al (2019) Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol 7(2):140–149. https://doi.org/10.1016/S2213-8587(18)30128-1
Ferland-McCollough D, Slater S, Richard J, Reni C, Mangialardi G (2017) Pericytes, an overlooked player in vascular pathobiology. Pharmacol Ther 171:30–42. https://doi.org/10.1016/j.pharmthera.2016.11.008
Lechner J, O’Leary OE, Stitt AW (2017) The pathology associated with diabetic retinopathy. Vision Res 139:7–14. https://doi.org/10.1016/j.visres.2017.04.003
Shin ES, Sorenson CM, Sheibani N (2014) Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res 9(3):362–373. https://doi.org/10.4103/2008-322X.143378
Wilkinson-Berka JL, Babic S, De Gooyer T et al (2004) Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 164(4):1263–1273. https://doi.org/10.1016/s0002-9440(10)63214-2
Cheng A, Dong Y, Zhu F, Liu Y, Hou FF, Nie J (2013) AGE-LDL activates Toll like receptor 4 pathway and promotes inflammatory cytokines production in renal tubular epithelial cells. Int J Biol Sci 9(1):94–107. https://doi.org/10.7150/ijbs.5246
Arias-Salvatierra D, Silbergeld EK, Acosta-Saavedra LC, Calderon-Aranda ES (2011) Role of nitric oxide produced by iNOS through NF-κB pathway in migration of cerebellar granule neurons induced by lipopolysaccharide. Cell Signal 23(2):425–435. https://doi.org/10.1016/j.cellsig.2010.10.017
Geraldes P, Hiraoka-Yamamoto J, Matsumoto M et al (2009) Activation of PKCδ and SHP1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 15(11):1298–1306. https://doi.org/10.1038/nm.2052
Rubsam A, Parikh S, Fort PE (2018) Role of inflammation in diabetic retinopathy. Int J Mol Sci 19(4):942. https://doi.org/10.3390/ijms19040942
Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65(1):116–128. https://doi.org/10.1111/j.1523-1755.2004.00367.x
Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM (2006) Impact of genetic background on nephropathy in diabetic mice. Am J Physiol Renal Physiol 290(1):F214–F222. https://doi.org/10.1152/ajprenal.00204.2005
Dharmarajan S, Fisk DL, Sorenson CM, Sheibani N, Belecky-Adams TL (2017) Microglia activation is essential for BMP7-mediated retinal reactive gliosis. J Neuroinflammation 14(1):76. https://doi.org/10.1186/s12974-017-0855-0
Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. https://doi.org/10.1038/nmeth.2019
Dharmarajan S, Gurel Z, Wang S, Sorenson CM, Sheibani N, Belecky-Adams TL (2014) Bone morphogenetic protein 7 regulates reactive gliosis in retinal astrocytes and Muller glia. Mol Vis 20:1085–1108
Scheef EA, Sorenson CM, Sheibani N (2009) Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol 296(4):C724–C734. https://doi.org/10.1152/ajpcell.00409.2008
Shin ES, Huang Q, Gurel Z et al (2014) STAT1-mediated Bim expression promotes the apoptosis of retinal pericytes under high glucose conditions. Cell Death Dis 5(1):e986. https://doi.org/10.1038/cddis.2013.517
Wassle H, Heinze L, Ivanova E et al (2009) Glycinergic transmission in the mammalian retina. Front Mol Neurosci 2:6. https://doi.org/10.3389/neuro.02.006.2009
Hammes HP, Lin JL, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51(10):3107–3112. https://doi.org/10.2337/diabetes.51.10.3107
Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS (2012) Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis Model Mech 5(4):444–456. https://doi.org/10.1242/dmm.009597
Gong MT, Li WX, Zhang Q et al (2018) Comprehensive analysis of gene expression profiles associated with proliferative diabetic retinopathy. Exp Ther Med 16(4):3539–3545. https://doi.org/10.3892/etm.2018.6635
Rashid K, Akhtar-Schaefer I, Langmann T (2019) Microglia in retinal degeneration. Front Immunol 10:1975. https://doi.org/10.3389/fimmu.2019.01975
Liu X, Xu B, Gao S (2021) Spleen tyrosine kinase mediates microglial activation in mice with diabetic retinopathy. Transl Vis Sci Technol 10(4):20. https://doi.org/10.1167/tvst.10.4.20
Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81(2):229–248. https://doi.org/10.1016/j.neuron.2013.12.034
Whitney IE, Keeley PW, St John AJ, Kautzman AG, Kay JN, Reese BE (2014) Sox2 regulates cholinergic amacrine cell positioning and dendritic stratification in the retina. J Neurosci 34(30):10109–10121. https://doi.org/10.1523/JNEUROSCI.0415-14.2014
Gu L, Xu H, Zhang C, Yang Q, Zhang L, Zhang J (2019) Time-dependent changes in hypoxia- and gliosis-related factors in experimental diabetic retinopathy. Eye 33(4):600–609. https://doi.org/10.1038/s41433-018-0268-z
Kinuthia UM, Wolf A, Langmann T (2020) Microglia and inflammatory responses in diabetic retinopathy. Front Immunol 11:564077. https://doi.org/10.3389/fimmu.2020.564077
Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C (2019) Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab 45(6):517–527. https://doi.org/10.1016/j.diabet.2019.04.002
Zudaire E, Gambardella L, Kurcz C, Vermeren S (2011) A computational tool for quantitative analysis of vascular networks. PLoS One 6(11):e27385. https://doi.org/10.1371/journal.pone.0027385
Li BY, Tan W, Zou JL et al (2021) Role of interferons in diabetic retinopathy. World J Diabetes 12(7):939–953. https://doi.org/10.4239/wjd.v12.i7.939
Tsalamandris S, Antonopoulos AS, Oikonomou E et al (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 14(1):50–59. https://doi.org/10.15420/ecr.2018.33.1
Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E (2019) Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol 18(1):72. https://doi.org/10.1186/s12933-019-0870-9
Yi Z, Li L, Garland A et al (2012) IFN-γ receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells. Eur J Immunol 42(8):2010–2018. https://doi.org/10.1002/eji.201142374
Gustavsson C, Agardh CD, Agardh E (2013) Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol 91(5):445–452. https://doi.org/10.1111/j.1755-3768.2012.02430.x
Quevedo-Martinez JU, Garfias Y, Jimenez J, Garcia O, Venegas D, Bautista de Lucio VM (2021) Pro-inflammatory cytokine profile is present in the serum of Mexican patients with different stages of diabetic retinopathy secondary to type 2 diabetes. BMJ Open Ophthalmol 6(1):e000717. https://doi.org/10.1136/bmjophth-2021-000717
Yao Y, Li R, Du J, Long L, Li X, Luo N (2019) Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis. Curr Eye Res 44(5):564–574. https://doi.org/10.1080/02713683.2019.1570274
Zhou J, Wang S, Xia X (2012) Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 37(5):416–420. https://doi.org/10.3109/02713683.2012.661114
Huang H, Gandhi JK, Zhong X et al (2011) TNFα is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 52(3):1336–1344. https://doi.org/10.1167/iovs.10-5768
Robinson R, Youngblood H, Iyer H et al (2020) Diabetes induced alterations in murine vitreous proteome are mitigated by IL-6 trans-signaling inhibition. Invest Ophthalmol Vis Sci 61(11):2. https://doi.org/10.1167/iovs.61.11.2
Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC (2000) Effect of cyclosporin-A on the blood–retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm 9(5):243–248. https://doi.org/10.1080/09629350020025764
Kowluru RA, Odenbach S (2004) Role of interleukin-1β in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 45(11):4161–4166. https://doi.org/10.1167/iovs.04-0633
Prantner D, Nallar S, Vogel SN (2020) The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways. FASEB J 34(12):15659–15674. https://doi.org/10.1096/fj.202002136R
Tang L, Xu GT, Zhang JF (2023) Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res 18(5):976–982. https://doi.org/10.4103/1673-5374.355743
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Data availability
All resources generated and/or analysed during the current study are included and available in the published article and online ESM files. All transgenic mouse lines used are commercially available.
Funding
ZQ and TLBA would like to gratefully acknowledge a Lilly Research Award. TLBA gratefully acknowledges an NIH Academic Research Enhancement Award (R15 EY033968). The work in the CMS and NS laboratories is supported by an unrestricted award from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences, the Retina Research Foundation, the RRF/Daniel M. Albert chair, and by National Institutes of Health grants P30 EY016665, R01 EY030076 and R01 EY032543. The sponsors of the study did not impose any restrictions regarding the publication of data.
Authors’ relationships and activities
ZQ and JMW are employed by Eli Lilly and Company. ZQ and TLBA were awarded a Lilly Research Award to investigate PDGFRβ in diabetic retinopathy. Funds were not related to drug development at Eli Lilly nor were any drugs tested in this study. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Contribution statement
TLBA, ZQ, JMW, SD, AJB, CMS, NS and CC were involved in the conception and design of the study, acquisition of data, or analysis and interpretation of data. All authors were involved in drafting or revising the article critically for important intellectual content and read and approved the final manuscript. TLBA is the guarantor of this work.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dharmarajan, S., Carrillo, C., Qi, Z. et al. Retinal inflammation in murine models of type 1 and type 2 diabetes with diabetic retinopathy. Diabetologia 66, 2170–2185 (2023). https://doi.org/10.1007/s00125-023-05995-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-023-05995-4